In order to evaluate the Dynasplint Trismus System (DTS) for the relief of trismus secondary to the treatment of head and neck cancer, we conducted a retrospective chart review of patients who had undergone DTS therapy during a 1-year period. Our inclusion criteria were cancer of the upper aerodigestive tract; treatment with radiation, chemotherapy, and/or surgery; and a maximal incisal opening (MIO) of less than 30 mm. MIO and the rate of improvement of trismus ("gain") were measured at selected intervals. Twenty-six patients met our study criteria; their pretherapy mean MIO was 19.3 mm. At the time of their most recent measurement, the mean MIO had increased to 25.5 mm-a measured gain of 32%. Although the initial rate of gain was 0.36 mm/day during the fi rst 6 weeks, improvement leveled off over time, and the overall rate of gain was 0.16 mm/day. We conclude that the DTS is eff ective in increasing the mandibular range of motion at a rate of change that is maximized during initial treatment.
Introduction
Trismus is a common sequela of multimodality treatment for head and neck cancer, and it can degrade oral hygiene, alter speech, limit diet, impede socialization, and complicate airway management. Although there is no universally accepted defi nition of or classifi cation system for trismus, most practitioners agree that the diagnostic criteria include a maximal incisal opening (MIO) of 20 to 35 mm. 1 Muscle infl ammation from surgery and radiation around the medial pterygoid muscles contributes to the disease etiology more than any specifi c temporomandibular joint insult. 2, 3 Aggressive physical rehabilitation, surgery, and home stretching exercises with or without the use of additional devices have been proposed as treatments for trismus. [4] [5] [6] Among the devices that have been evaluated are sequential tongue blades, tapered screws with increasing diameter shaft s, the Th eraBite system (Atos Medical; West Allis, Wis.) and, most recently, the Dynasplint Trismus System (DTS) (Dynasplint Systems; Severna Park, Md.). Th e Th eraBite system has been found to increase MIO in longstanding trismus by as much as 13.6 mm. 4 Initially developed to manage limb contractures aft er traumatic and neuorologic injuries, Dynasplint devices have been found to improve elbow fl exion, as well. 7, 8 Th ese devices provide passive sustained tension on affected joints to allow for a gradual increase in range of motion. For the treatment of trismus, the device is fi t to patients with a molded mouthpiece, which minimizes the amount of active patient participation needed to hold it in place (fi gure 1).
In theory, the DTS allows for consistent low-pressure stretching of collagen fi bers, and thus it accelerates the minute until they reached their goal for a given MIO. As each goal was reached, a new goal was established for a new MIO setting.
In addition to demographic data, we compiled information on the specifi c diagnosis, cancer stage, and previous treatments, including radiation exposures. MIO was measured with an angled ruler that is provided with the DTS kit (fi gure 1). MIOs were recorded at the initial evaluation and monthly thereaft er, as well as during clinic follow-ups and routine medical visits over the course of treatment. Statistical analysis was performed with the Fisher exact test and two-tailed p values. Follow-up was limited for 4 of the 26 patients (15%) because they had begun using the DTS near the end of the year-long data compilation period, and their MIOs beyond the 4-week interval were therefore not included in the data analysis.
Results
A total of 27 patients were screened, and 1 was excluded because of the presence of a buccal abscess that contributed to his trismus (MIO: 5 mm). Th erefore, the fi nal study population was made up of 26 patients-20 men and 6 women, aged 37 to 80 years (mean: 63.3 ± 11.7). Patient demographics, tumor site, and the type of oncologic treatment are shown in table 1.
Th e pathologic diagnosis was squamous cell carcinoma in 25 patients (96%) and ameloblastoma in 1 (3.8%). With the exception of 2 patients whose tumor stage was unknown, all the squamous cell carcinomas were documented as either stage III or IV; the stage of remodeling of the deformed tissue without triggering elastic rebound or infl ammatory insult. However, to date, this system not been extensively evaluated. Because this therapy is associated with signifi cant costs and neither its eff ectiveness nor its optimal treatment duration have been established, we undertook a study at our tertiary care institution to evaluate patients who had been treated with the DTS to relieve trismus resulting from the treatment of cancer of the upper aerodigestive tract.
Patients and methods
For this retrospective case series analysis, all patients who had undergone DTS therapy from August 2006 through July 2007 were screened for study eligibility. Inclusion criteria were a diagnosis of upper aerodigestive tract cancer; treatment with radiation, chemotherapy, and/ or surgery; and an opening of less than 30 mm between the upper and lower incisors. Exclusion criteria were age younger than 19 years and the presence of severe periodontal disease, abscess, or other infectious process that could limit mandibular mobility.
All patients had been treated by a team of head and neck surgeons, radiation oncologists, a reconstructive surgeon, and a speech pathologist. Patients received instructions and fi tting for the DTS device by a manufacturer's representative prior to initiating home therapy. Th ey were examined 10 to 14 days aft er fi tting and thereaft er at routine monthly visits, as well as at their regularly scheduled medical appointments with physicians and the speech pathologist. Th erapy sessions were held for 20 to 30 minutes three times a day. Patients were encouraged to increase the length of each session by 1 Figure 1 . Th e DTS device is shown along with accompanying supplements, which include green paste for molded fi tting and an angled ruler for measuring minimal incisal opening. the ameloblastoma was also unknown. Patients had received treatment for their head and neck cancer from 1988 through 2006. Th e median length of time between treatment and fi tting for DTS therapy was 36 months (range: 5 mo to 18 yr). By the time of data compilation, 11 patients (42%) had discontinued DTS therapy. Among the reasons for discontinuation were 1 case each of death from an unspecifi ed cause, broken dental bridgework, fi nancial limitations, and a failure to improve aft er 26 weeks of therapy, with an overall gain of 5 mm in MIO; no reason was specifi ed for the other 7 discontinuations.
Th e length of treatment ranged from 1 to 28 weeks (mean: 12 ± 8.6). Data on incisal measurements and gain are shown in table 2.
Four-week data. A total of 7 patients used the DTS for 4 weeks or less, and 19 patients used it for more than 4 weeks. For the former group, the mean fi nal gain was signifi cantly less than it was for the latter group (2.79 vs. 6.87 mm; p = 0.0006) (fi gure 2).
Six-week data. Aft er 6 weeks of therapy, the mean rate of gain at 2-week intervals among the 17 patients who remained was signifi cantly less than it had been previously (0.36 vs. 0.034 mm; p < 0.0001) (fi gure 3).
Th e mean interval MIO was based on the most recent measurement available at each interval.
Ten-week-plus data. A total of 11 patients (42%) used the device for more than 10 weeks. Th e mean time between individual measurements during the fi rst 10 weeks was 22 ± 13 days, and the mean interval between measurements aft er 10 weeks was 94 ± 40 days. Th e mean MIO for the cohort at 2-week intervals for the fi rst 10 weeks is shown in fi gure 4.
Cumulative data. Th e mean overall rate of gain from the initial MIO measurement to the fi nal measurement was 0.16 ± 0.14 mm/day. When adjusted for only those patients who completed 10 weeks of therapy, the mean fi nal gain was 7.0 ± 3.1 mm. Individual measurements of rate of gain are shown in fi gure 5.
Discussion
Tongue blades and passive range-of-motion exercises are common initial treatments for trismus because of their low cost and ease of learning. In addition, few studies have provided any strong clinical evidence that newer devices have any signifi cant advantage over these simpler measures. 9 However, DTS therapy does appear to result in a signifi cant improvement in MIO for patients with trismus secondary to previous head and neck cancer treatment. Th e greatest improvement occurs during the fi rst 6 weeks of therapy. While gains in MIO are greater when the device is used for more than 4 weeks, the rate of gain drops precipitously aft er 6 weeks.
In our study, the mean initial MIO was 19.3 ± 5.0 mm, which is comparable to the 21.3 ± 1.7 mm previously reported by Buchbinder et al. 4 Also, the mean gain for our entire cohort (6.2 mm ± 3.4 mm) is comparable to that seen with tongue blades and range-of-motion exercises measured in the Buchbinder et al study. Of note, our patients were followed more closely toward the beginning of the study period rather than later, and their MIOs were not measured aft er their discontinuation of therapy to assess for rebound trismus. Th is might limit the validity of fi ndings with regard to the true rate of gain possible with the DTS. Th e issue of compliance is important in comparing Figure 2 . Graph compares the fi nal gain in mean maximal incisal opening (MIO) between patients who used the device for 4 weeks or less and those who used it for more than 4 weeks. Th e diff erence was statistically signifi cant (p = 0.0006). In the study by Buchbinder et al, several patients experienced an interval decrease in gain at some clinic visits, although all patients achieved an overall increase aft er the entire length of therapy. 4 We detected a decrease in the rate of gain aft er 6 weeks of use, but no patient in our study demonstrated a decrease in MIO between interval measurements. Th e possibility of confounding variables such as gaps in compliance and the onset of patient burnout might have contributed to our long-term fi ndings.
Cohen et al investigated the role of expansion devices early in the postoperative setting, and they reported no complications. 10 In that study, devices were used to prevent rather than treat trismus. In fact, one of those patients had a pretreatment MIO of 38 mm. In our study, the mean interval between oncologic treatment and the initiation of DTS therapy was roughly 4 years, which provided the DTS team with ample time to select patients with severe and longstanding trismus that required intervention.
In a more recent report, Stubblefield et al demonstrated a 5-mm gain over an average of 118 days (~17 wk). 11 In that study, compliant patients demonstrated greater gain than did noncompliant patients. Our study reproduced those fi ndings, and it provided information on how the rate of improvement in gain is important in determining the duration of therapy necessary to obtain maximal results.
Given that those patients in our study who used the DTS device for less than 4 weeks fared worst and that the rate of gain seemed to decrease aft er extended use of the DTS, we believe that 6 weeks is long enough for an adequate trial of DTS therapy, and we note that the rate of improvement can be expected to decline with continued use. While the accuracy of our fi ndings is limited by the sporadic nature of the intervals between follow-up measurements, 17 of our 26 patients (65%) did receive at least 6 weeks of DTS therapy. Some studies of other trismus devices fi nished with as few as 7 and 9 patients. 4, 10 A recent study by Shulman et al also demonstrated measurable improvement in trismus with the DTS. 12 Compared with our study, their mean initial MIO was not as severe (24.97 ± 9.64 mm vs. 19 ± 5.0 mm), and their defi nition of trismus was less stringent (MIO <40 mm vs. <30 mm). Our study focused on trismus resulting from the treatment of head and neck cancer only; the study by Shulman et al 12 included patients with trismus secondary to stroke and dental and oral surgery. Nevertheless, the fi nding that the DTS is eff ective in treating trismus of other etiologies is encouraging.
Given the altered muscle control, fatigue, and poor dental hygiene associated with head and neck cancer treatment, maintaining a device in the oral cavity can be diffi cult. Th e fi tted DTS molding secures the device during therapy sessions, even in edentulous patients. Once the device is placed, pressure is applied with a steady force for the duration of the session, which can last as long as 30 minutes. With other devices, simple plastic plates and foam protect the dentition and gums from abrasive forces, but they do little to prevent dislodging during the application of tension. Also, the need for active manipulation during sessions limits the ability of patients to perform other tasks simultaneously.
At approximately $465 per month, DTS therapy costs much more than Th eraBite treatment, which involves a one-time payment of roughly $400; it is also much more expensive than tongue blade and range-of-motion exercises. Financial concerns and a lack of insurance reimbursement for DTS therapy did contribute to the premature discontinuation of the DTS by 1 of our patients.
In conclusion, we found that the DTS is a safe and eff ective therapy for trismus secondary to the treatment of head and neck cancer. Th e device can provide an impressive gain in MIO during the fi rst 6 weeks of therapy. Given the signifi cant costs associated with this therapy and the decrease in the rate of benefi t aft er 6 weeks, we believe that 6 to 8 weeks is a reasonable length of time to undergo therapy. Our fi ndings suggest a role To gain unlimited access to all the articles and features on entjournal.com, simply fill out the brief registration form at www.entjournal.com and start enjoying everything the online journal has to offer! for further investigations into trismus rehabilitation with the DTS. Comparisons of the DTS device with the Th eraBite device and with tongue blades have not been statistically assessed. Given the impressive early response to the DTS in our study, a trial of DTS therapy followed by a less expensive maintenance therapy may provide an ideal regimen.
experience a complete resolution of symptoms. Our own experience was consistent with this fi nding. Practicing otolaryngologists must be cognizant of this disease process and its appropriate treatment possibilities. Furthermore, it is imperative that practitioners consider systemic infl ammatory diseases when a patient presents with an isolated infl ammatory pseudotumor, which may be a harbinger of more widespread disease.
In conclusion, as this case shows, sclerosing infl ammatory pseudotumor can be localized to the maxillary sinus without orbital involvement. Th e traditional treatment of oral steroids for nonsclerosing pseudotumors may not be eff ective for patients with the fi brosclerotic variant. Surgical excision is a viable treatment alternative. Clinicians should be aware of the rare presentation of fi brosclerotic pseudotumor when exploring a mass lesion of an infl ammatory nature in the maxillary sinus.
